Connect with us

Technology

Ember LifeSciences and Alfresa Corporation Enter into Capital and Business Alliance to Improve the Quality of the Pharmaceutical Cold Chain in Japan

Published

on

Ember offers Japanese market pharmaceutical transportation solution integrating temperature control, visualization of transportation status and traceability

LOS ANGELES, July 29, 2026 /PRNewswire/ — Ember LifeSciences, Inc. (“Ember”), an award-winning provider of advanced pharmaceutical cold chain solutions, has entered into a capital and business alliance with Alfresa Corporation (“Alfresa”), a subsidiary of Alfresa Holdings Corporation.

The Alfresa Group has the No. 1 domestic net sales in the pharmaceutical wholesale business in Japan. Alfresa will partner with Ember to improve the quality of pharmaceutical cold chain logistics across Japan, including evaluating the Ember Cube and related technologies for Alfresa’s Home Care Delivery service, which delivers specialty pharmaceuticals directly from medical institutions to patients’ homes.

As part of the new alliance, Alfresa will provide financial support for Ember’s business expansion through an investment in Series A preferred stock issued by Ember, strengthening collaboration between the two companies. Other investors in the Ember Series A include Amgen, Cardinal Health, Carrier and Sea Court Capital. Through the agreement, Alfresa obtains the exclusive sales rights in Japan’s healthcare sector for solutions provided by Ember.

“We are deeply honored to partner with Alfresa, a company whose legacy of excellence and market leadership we hold in the highest regard,” said Clay Alexander, Ember founder and CEO. “As our Ember Cube 2 continues to gain international acclaim for its revolutionary design, this strategic investment and distribution alliance marks a pivotal milestone. Together, Alfresa and Ember share a profound commitment to bringing unprecedented precision, confidence and reliability to pharmaceutical cold chain logistics for patients throughout Japan.”

“The rapid growth of biopharmaceuticals and vaccines — with the number of temperature‑sensitive products increasing each year — demands absolute precision in cold chain logistics,” said Yusuke Fukujin, representative director and president, Alfresa. “Alfresa has been strengthening its capabilities in this space through continuous investment in next generation technologies. I am very excited about this partnership with Ember, which reinforces our commitment to advance cold chain pharmaceutical logistics in the Japanese market.”

Ember provides pharmaceutical manufacturers, distributors and healthcare providers with cold chain solutions that combine temperature control with real-time shipment visibility. The Ember Cube 2, which recently earned the Best of the Best Red Dot Design Award, maintains a temperature range of 2°C to 8°C for more than 72 hours while continuously monitoring shipment conditions and location. Its reusable design also helps reduce packaging waste compared with traditional single-use shipping materials.

About Ember LifeSciences
Ember LifeSciences initially launched as an offshoot of Ember Technologies’ “Ember,” the design-led temperature control brand and maker of the award-winning temperature control mug, which has surpassed half a billion dollars in total sales to date. Ember seeks to redefine global medicine distribution through leveraging Ember’s proprietary temperature control technology to improve the way we transport life-saving medicines and vaccines around the world. To learn more about Ember LifeSciences, visit emberlifesciences.com.

Media Contact
Meghan Bianco
embermedia@rfbinder.com

About the Alfresa Group
The Alfresa Group is a leader in the Japanese healthcare industry and is dedicated to making its corporate philosophy, “we create and deliver a fresh life for all,” come true through a wide range of business lines, including ethical pharmaceuticals wholesaling, OTC pharmaceuticals wholesaling, pharmaceutical manufacturing, operating dispensing pharmacies, regenerative medicine-related business, and CRO business. Alfresa Holdings Corporation (TSE:2784) reported consolidated revenue of ¥3.1 trillion for the fiscal year ended March 31, 2026. For more information, please see: https://www.alfresa.com/eng/ 

Media Contact
ir@alfresa.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/ember-lifesciences-and-alfresa-corporation-enter-into-capital-and-business-alliance-to-improve-the-quality-of-the-pharmaceutical-cold-chain-in-japan-302838262.html

SOURCE Ember LifeSciences, Inc.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Ready Server Pilots Full-Immersion Cooling to Prepare Singapore Facility for AI-Ready Compute Services

Published

on

By

VPS provider deploys self-built liquid cooling solution to increase rack density and energy efficiency amid surging compute demand

SINGAPORE, July 30, 2026 /PRNewswire/ — Ready Server, a Singapore-based VPS Hosting and server solutions provider, has completed its first pilot of full-immersion liquid cooling at its data centre facility in Singapore, marking a key step in its roadmap toward delivering AI-ready infrastructure services.

The pilot involves immersing complete server hardware — production-grade AMD-based servers with memory and storage components — into a tank of non-conductive immersion cooling fluid, using immersion cooling hardware from US-based liquid cooling specialist GRC. The immersion cooling fluid transfers heat away from server components far more efficiently than air, enabling higher rack densities and potentially reducing cooling energy consumption.

Meeting the demands of the AI era

Global demand for high-performance compute, accelerated by AI workloads, is pushing data centre operators worldwide to rethink how densely and efficiently servers can be deployed. As computing systems become more powerful and valuable, operators are seeking more efficient cooling technologies to maximise performance while making better use of existing space and power resources.

Rather than purchasing fully packaged immersion-cooled systems, Ready Server opted for a self-deployed solution — designing a customised setup tailored to its existing facility. This approach reduces capital costs while building in-house engineering capability in liquid-cooled operations.

“Everything comes with a risk, so we have to take some that will enable us to compete and deliver the performance needed in the future,” said Alan Woo, Director of Ready Server, who personally oversaw the import and installation of both the cooling tank and immersion cooling fluid.

A pragmatic, phased approach

Ready Server’s pilot methodology reflects careful risk management. Servers selected for immersion are units that have already operated in racks for approximately two years — nearing the end of their manufacturer warranty — since immersion and hardware modifications can affect warranty coverage. Components are prepared prior to immersion: cooling fans are removed, thermal paste is replaced with a thin metal foil suited to liquid-cooled operation, and certain paper labels or adhesive stickers are removed, as prolonged exposure to the fluid can cause them to deteriorate.

Compared with alternative liquid cooling methods the company has previously trialled, including spray-based coolant jets, the full-immersion approach offers simpler maintenance and continuous 24/7 operation, and reduces the risk of coolant leaks associated with direct-to-chip liquid cooling.

Building toward AI-ready services

The pilot delivers benefits beyond electricity savings: it equips Ready Server with the operational experience needed to design future rack architectures for compute-intensive workloads.

“This journey into liquid cooling has taught us valuable lessons in designing our future racks and how we can deliver more compute-heavy services to customers,” said Woo. “By investing in the technology and also the capabilities to run it, we are more ready to offer new services that the market is asking for.”

Ready Server plans to apply learnings from the pilot as it expands its portfolio of high-density hosting and AI-ready data centre services in Singapore.

About Ready Server

Ready Server is a leading Singapore-based VPS hosting provider in the Asia-Pacific region. Delivering high-performance, enterprise-grade infrastructure, and a robust network of data centers spanning Singapore, Hong Kong, and Tokyo, the company offers elite, low-latency connectivity and unmetered bandwidth designed for demanding digital workloads. With flexible per-hour billing, empowering developers and enterprises to scale instantly across major Asian hubs with superior reliability, connectivity and ease. https://www.readyserver.sg/

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/ready-server-pilots-full-immersion-cooling-to-prepare-singapore-facility-for-ai-ready-compute-services-302837894.html

SOURCE Ready Server

Continue Reading

Technology

Mitrade Enters Bloomberg.com Partnership as Asian Traders Face Blurring Line Between Credible Insight & Online Influence

Published

on

By

BANGKOK, July 30, 2026 /PRNewswire/ — Award-winning global CFD broker Mitrade today announced a partnership with Bloomberg.com amid a financial information landscape in which institutional reporting, social commentary and competing finfluencer narratives vie for traders’ attention.

Across Asia, online influence can gain momentum faster than information can be verified. Greenwich Associates found that investors in the region were consistently heavier users of all forms of social sources than their counterparts in North America and Europe – a behavior heightening the importance of distinguishing reach from reliability.

That distinction underpins the partnership. As financial markets become increasingly influenced by information from multiple sources, Mitrade recognises the importance of credible business and financial reporting in helping market participants place developments in context.

“We see across Asia that distinguishing credible reporting from online influence has become fundamental to financial literacy,” said Kevin Lai, vice president of Mitrade Group. “At Mitrade, we believe no financial development exists in isolation. Understanding the wider context helps connect the dots between events and their broader market implications. We are beginning the partnership in Australia through an initial Bloomberg.com subscription initiative, and our global presence gives us scope to explore its broader potential over time.”

The announcement marks another step in Mitrade’s development as a fintech brand. The broker has received 65 industry awards, including recent honours for regulatory standards, trader education and CFD brokerage—recognition that reinforces the standards underpinning its growth. 

About Mitrade Group

Mitrade is a globally recognised, award-winning CFD trading platform licensed under the Cayman Islands’ CIMA (SIB1612446), Mauritius’s FSC (GB20025791), Australia’s ASIC (AFSL398528), South Africa’s FSCA (FSP 54842), UAE’s CMA (20200000397), and Cyprus’s CySEC (CIF438/23).

The group democratises market access, connecting 7M+ traders to 1,000+ OTC derivatives, including indices, forex, commodities, ETFs, and shares.

The platform offers millisecond execution, tight spreads, advanced risk mitigation, and multi-device compatibility, ensuring an intuitive trading experience tailored to every trader.

Trading involves risks. This article is for informational purposes only and not financial advice, an offer, or a solicitation.

Visit https://www.mitrade.com for more information.

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/mitrade-enters-bloombergcom-partnership-as-asian-traders-face-blurring-line-between-credible-insight–online-influence-302837599.html

SOURCE Mitrade Group

Continue Reading

Technology

Medidata Launches Medidata Plus, an AI-Native Foundation Built to Scale Clinical Portfolios

Published

on

By

Built on an award-winning AI foundation, Medidata Plus removes traditional barriers, empowering sponsors and CROs to scale intelligence across entire portfolios

SINGAPORE, July 30, 2026 /PRNewswire/ — Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions, today announced the launch of Medidata Plus. This clinical artificial intelligence layer unlocks the full breadth of AI capabilities across the Medidata Platform, giving sponsors access to scalable, outcome-driven AI throughout their global portfolios. Medidata Plus shifts the life sciences industry away from a legacy of disjointed, inefficient point solutions to a unified, end-to-end AI strategy, accelerating the delivery of life-saving therapies to patients.

While 92% of industry decision-makers plan to increase AI investment, only 29% say AI currently meets or exceeds their expectations. Medidata Plus addresses these systemic roadblocks directly, turning unpredictable AI costs into a streamlined, predictable investment by standardizing the data layer across the entire clinical trial lifecycle.

“Stitching together point solutions isn’t a strategy — it’s a liability. Drug development’s next leap will come when AI is consistent, connected, and portfolio-wide,” said Dr. Nimita Limaye, Research VP, Life Sciences R&D Strategy and Technology, IDC. “Medidata Plus delivers this with a cohesive AI layer across the entire lifecycle, shifting organizations from sporadic AI adoption to a continuous, portfolio-wide strategy that drives real clinical outcomes.” 

Medidata Plus brings AI-driven intelligence to every stage of a clinical trial, from study build to data management to ongoing risk monitoring. Rather than relying on a patchwork of disconnected tools, study teams can access a single, unified layer of AI capabilities built to accelerate execution and surface insights in real time. Key capabilities made accessible through Medidata Plus include:

Study Builds Accelerated with AI: Reduces study build timelines from weeks to mere hours by automating EDC and eCOA design, and generating synthetic patient data for user acceptance testing, dramatically accelerating study startup times.No-Code Data Transformation: Through enhanced AI interoperability, Medidata Plus seamlessly ingests, standardizes, and transforms data from clinical and real-world sources to extract insights without writing a single line of code.Proactive De-risking: Embedded analytics instantly flag critical enrollment downtrends or safety signals, reducing mid-cycle pauses and accelerating inspections.Companioning Audit Exploration: Agentic AI supports study teams to mine their end-to-end audit history using natural-language queries, transforming complex regulatory data into actionable insights in minutes.

“We’ve listened to our customers and they’re clear that AI can transform clinical trials, but not as an army of agents from disparate sources trained in disparate ways,” said Anthony Costello, CEO, Medidata. “Medidata Plus is a drop-in AI strategy for clinical research that upskills teams, automates workflows, and surfaces insights at a pace that’s redefining what teams thought was possible. We are in conversations with dozens of customers about making this shift and what we’re hearing tells us the industry has been waiting for exactly this.”

Life sciences organizations, ranging from enterprise biopharma leaders to global CROs, are poised to unlock significant value through Medidata Plus, which provides them with a decisive technological edge to execute clinical trials with greater precision, higher quality, and accelerated timelines. 

The launch of Medidata Plus establishes a future-ready framework for platform advancement. As Medidata continues to embed clinically-fluent AI across its ecosystem, study teams from sponsors and CROs will gain access to an expanding suite of capabilities that deliver value across their trial portfolios.

Backed by an AI infrastructure recently recognized with the highest “Luminary” rating in Everest Group’s AI Innovation Watch Report, Medidata’s AI continues to set the standard in clinical trials, having supported 80% of FDA novel drug approvals in 2025. To learn more about how Medidata Plus delivers an easy, fast, and AI-powered clinical research experience, visit here

About Medidata 

Medidata has been powering smarter treatments and healthier people by supporting clinical trials through groundbreaking technological innovations for over 25 years. Medidata is a leader in AI-powered solutions across the entire trial lifecycle to accelerate clinical breakthroughs, reduce patient and site burden, and bring new therapies to market faster. Supported by one of the largest clinical datasets in the industry of more than 38,000 trials and 12 million patients, Medidata’s Study, Patient, and Data Experiences are trusted by more than 1 million registered users across approximately 2,300 customers. A Dassault Systèmes brand (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City and is recognized as a leader by Everest Group and IDC. Discover more at www.medidata.com. Listen to our latest podcast, from Dreamers to Disruptors, and follow us at @medidata-solutions on LinkedIn. 

About Dassault Systèmes

Dassault Systèmes is a catalyst for human progress. Since 1981, the company has pioneered virtual worlds to improve real life for consumers, patients and citizens. Through the 3DEXPERIENCE platform, AI-powered, science-based virtual twins help 390,000 customers of all sizes, in all industries, collaborate, imagine and create sustainable innovations that drive meaningful impact. For more information, visit: www.3ds.com

Contact:  

For interviews and questions, please contact Medidata PR 

Medidata.PR@3ds.com  

Analyst Relations 

Medidata.AR@3ds.com  

View original content to download multimedia:https://www.prnewswire.com/in/news-releases/medidata-launches-medidata-plus-an-ai-native-foundation-built-to-scale-clinical-portfolios-302838472.html

Continue Reading

Trending